1st Quarter - Report

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$693,081
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 13, 2017 $693,081 Replaced
1st Quarter - Amendment Apr 13, 2017 $693,081 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Issues related to prescription drug abuse. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). H.R.749/S.297, Lower Drug Costs through Competition Act HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, FDA user fees, manufacturer market and data exclusivity, REMS, biosimilars.

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
MARK D MERRITT —
KATHERINE C. MURPHY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Federal Trade Commission (FTC); Food & Drug Administration (FDA)

Bills named: S. 413 (115th), H.R. 1038 (115th), H.R. 1316 (115th), H.R. 749 (115th), S. 297 (115th), S. 637 (115th), S. 771 (115th)

Pharmacy PHA

Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
MARK D MERRITT —
KATHERINE C. MURPHY —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: S. 771 (115th), S. 413 (115th), H.R. 1038 (115th), H.R. 1316 (115th), S. 637 (115th)

Medicare/Medicaid MMM

Issues related to pharmaceutical manufacturer and pharmacy contracting with respect to drug pricing. Regulatory and proposed legislative changes to Medicare Part D including non-interference, Direct and Indirect Remuneration (DIR), pharmacy networks, classes of clinical concern, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse in Medicare. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, e-prescribing, PBM disclosure requirements, specialty pharmacy, mail-service pharmacy, formulary transparency, and medical loss ratio). HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
MARK D MERRITT —
KATHERINE C. MURPHY —

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); SENATE

Bills named: H.R. 1038 (115th), H.R. 1316 (115th), S. 413 (115th), S. 637 (115th), S. 771 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.